EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements

Pia Mouhanna iD, Anders Ståhlberg iD, Daniel Andersson, Ahmed Albu-Kareem, Ellinor Elinder, Olle Eriksson, Amy Kavanagh, Anikó Kovács, Karolina F Larsson, Barbro Linderholm, Monika Uminska, Tobias Österlund und 2 weitere

International Journal of Cancer · 15.04.2025 · 156 (8) · 1509-1517

DOI: 10.1002/ijc.35292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 18.12.2024. Verfasst von Pia Mouhanna und 13 weiteren Autor:innen. Beteiligte Einrichtung: Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, G…. Hauptthemen laut MEDLINE: Breast Neoplasms, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ALF grants, Region Östergötland, The Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALF), The Christie Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumour DNA (ctDNA) is an emerging biomarker for monitoring cancers. The personalised disease monitoring in metastatic breast cancer (PDM‐MBC) study is an ongoing study instigated to evaluate ctDNA as a biomarker to individualise imaging requirements in patients with MBC. Patients receiving first‐line endocrine therapy (aromatase inhibitor + cyclin‐dependent kinase 4/6 inhibitor) had plasma samples collected pre‐treatment, weeks 2 and 4, and concurrently with imaging until progressive disease (PD). Here, we apply an experimental analytical workflow for ultrasensitive ctDNA analysis, utilising personalised ctDNA panels designed from mutations identified in tumour tissue, and present results for 24 patients. Twenty patients (83%) had detectable ctDNA pre‐treatment. The median progression‐free survival was 25.6 months, and 13 patients experienced PD, with rising ctDNA detected at or prior to PD in 12 patients (92%). If imaging had been omitted until the detection of rising ctDNA for at least one mutation, 68% ( n = 71) of the scans performed amongst ctDNA‐positive patients would have been avoided. Our results demonstrate that integration of personalised ctDNA monitoring of patients with MBC has potential to substantially reduce the imaging needs in patients showing ctDNA response to treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCirculating Tumor DNABiomarkers, TumorHumansFemaleMiddle AgedAgedPrecision MedicineMutationAdultNeoplasm Metastasis

Stichwörter der Autor:innen

breast cancerctDNAimagingliquid biopsyprecision medicine

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Oncology, Ryhov County Hospital, Jönköping, Sweden.
  • Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Department of Oncology, Linköping University Hospital, Linköping, Sweden.
  • Department of Oncology, Södersjukhuset, Stockholm, Sweden.

ORCID-Profile: Pia Mouhanna, Anders Ståhlberg, Sacha J Howell, Maria Ekholm

Förderung

  • ALF grants, Region Östergötland
  • The Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALF)
  • The Christie Charity
  • Foundation Assar Gabrielsson
  • Foundation for Clinical Cancer Research in Jönköping
  • Futurum - the Academy for Health and Care
  • Gunnar Nilsson Cancer Foundation
  • Kronoberg Cancer Foundation

Zitieren

APA

Mouhanna, P., Ståhlberg, A., Andersson, D., Albu-Kareem, A., Elinder, E., Eriksson, O., Kavanagh, A., Kovács, A., Larsson, K. F., Linderholm, B., Uminska, M., Österlund, T., Howell, S. J., & Ekholm, M. (2025). Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements. International Journal of Cancer, 156(8), 1509-1517. https://doi.org/10.1002/ijc.35292

Vancouver

Mouhanna P, Ståhlberg A, Andersson D, Albu-Kareem A, Elinder E, Eriksson O, et al. Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements. International Journal of Cancer. 2025;156(8):1509-1517. doi:10.1002/ijc.35292

BibTeX
@article{Mouhanna2025,
  author = {Mouhanna, Pia and Ståhlberg, Anders and Andersson, Daniel and Albu-Kareem, Ahmed and Elinder, Ellinor and Eriksson, Olle and Kavanagh, Amy and Kovács, Anikó and Larsson, Karolina F and Linderholm, Barbro and Uminska, Monika and Österlund, Tobias and Howell, Sacha J and Ekholm, Maria},
  title = {Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements},
  journal = {International Journal of Cancer},
  year = {2025},
  volume = {156},
  number = {8},
  pages = {1509--1517},
  doi = {10.1002/ijc.35292}
}
Kostenlos starten →